OKYO Pharma Ltd

OKYO Pharma Ltd (OKYO) priced its initial public offering on May 18, 2022 at $4.00 per ADS, above its $0.056–$0.191 range, raising $2.5M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $87.1M. ThinkEquity was lead-left underwriter. Orrick, Carey Olsen and Sheppard Mullin advised the company and Dorsey & Whitney advised the underwriters.

OKYO Pharma Ltd is a preclinical biopharmaceutical company developing therapeutics for inflammatory eye diseases and ocular pain. Its research targets a novel G protein-coupled receptor, and its lead preclinical candidate, OK-101, is being developed for dry-eye disease.

Status

IPO

Ticker

OKYO

Exchange

Nasdaq Capital Market

Priced

May 18, 2022

IPO price

$4.00 per ADS

Price range

$0.056–$0.191

Raised

$2.5M

Market cap at IPO price

$87.1M

First filed

Mar 4, 2022

Underwriters

ThinkEquity

Company counsel

Orrick, Carey Olsen and Sheppard Mullin

Underwriters' counsel

Dorsey & Whitney

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.